Point-of-Care Testing and Compliance

Point-of-Care Testing, Compliance, and Regulation

Point-of-care testing (POCT) places a laboratory examination near the patient in an emergency department, operating room, clinic, pharmacy, nursing unit, mobile service, or home. The shorter path from specimen to result can support a faster decision. Devices, reagents, records, and operators are distributed across several settings and require one coordinated quality system. Under the Clinical Laboratory Improvement Amendments (CLIA), POCT can be waived, moderate complexity, or high complexity.¹

Moving an examination closer to the patient changes the workflow around the measurement. The laboratory controls the full path from test selection through result reporting.

POCT feature	Possible benefit	Control needed
Testing near the patient	Shorter turnaround and earlier availability of a result	A defined response pathway for critical, unexpected, or instrument-flagged results
Small specimen volume	Less blood loss and an easier collection from some patients	Correct capillary or whole-blood collection, adequate volume, and control of tissue-fluid contamination
Little or no specimen transport	Fewer transport delays and temperature excursions	Patient identification, specimen identification, and direct transfer of the result into the correct record
Many devices and operators	Testing can be available across several care settings	Device and operator inventories, current procedures, training, authorization, quality-control (QC) review, and traceability
A rapid single-use or cartridge system	Few manual analytic steps	Compliance with the intended use, storage limits, timing, environmental limits, and error-code instructions
A method different from the central laboratory	A result can be produced with a specimen type suited to near-patient use	Defined comparability, reportable range, interferences, units, reference or decision limits, and confirmation rules

Per-test consumable costs can be higher than central testing, and the distributed program requires time for coordination, connectivity, competency assessment, and record review. The value of POCT therefore depends on the complete clinical and laboratory workflow, including the action taken when the result becomes available.

Test complexity and certificate scope

The exact test system, intended use, and instructions determine its CLIA category. FDA assigns commercially marketed systems to one of three categories using seven criteria: required knowledge; training and experience; reagent preparation; operational steps; calibration, QC, and proficiency-testing materials; troubleshooting and maintenance; and interpretation and judgment. A total score of 12 or less is moderate complexity, and a score above 12 is high complexity. An uncategorized system defaults to high complexity until it is categorized.^2,3

Category	Regulatory meaning	Main operational consequence
Waived	A system listed by regulation, cleared for home use, or granted waived status because it meets the statutory simplicity and risk criteria	Obtain an appropriate CLIA certificate and follow the current manufacturer instructions. State, accreditation, and facility rules may add training, competency, QC, or proficiency requirements.
Moderate complexity	A system with an FDA complexity score of 12 or less	Meet the applicable nonwaived requirements for personnel, procedures, performance verification, QC, proficiency testing or alternative assessment, competency, records, and survey.
High complexity	A system with a score above 12, an uncategorized system, or a method treated as high complexity after a modification that affects performance	Meet the high-complexity personnel and quality-system requirements and establish performance specifications when required.

Provider-performed microscopy. Provider-performed microscopy (PPM) procedures form a subcategory of moderate-complexity testing. A physician, dentist, or midlevel practitioner authorized under state law performs specified microscopy during the patient’s visit using a bright-field or phase-contrast microscope. A Certificate for PPM Procedures covers those procedures and waived testing.^2,4

CLIA recognizes five certificate categories. Four are continuing certificate types, and the Certificate of Registration is a temporary status while a laboratory seeks a Certificate of Compliance or Accreditation.^2,4

Certificate	Testing covered
Certificate of Waiver	Waived testing
Certificate for PPM Procedures	Specified PPM procedures and waived testing
Certificate of Registration	Temporary authority for nonwaived testing while the compliance survey or accreditation process is pending
Certificate of Compliance	Waived and applicable nonwaived testing after a CMS or state survey finds compliance with CLIA
Certificate of Accreditation	Waived and applicable nonwaived testing after accreditation by a CMS-approved organization within its approved scope

Each fixed testing location generally files a separate CLIA application. The federal rules provide limited exceptions for mobile or temporary testing sites, certain nonprofit or government public-health laboratories performing no more than a combined 15 moderate-complexity or waived tests per certificate, and hospital laboratories in contiguous buildings on the same campus, under common direction, and within the same physical location or street address. Before a POCT service begins, the laboratory confirms that the location, specialty or subspecialty, and highest test complexity fit the certificate.^2,4,5

Oversight of a distributed testing program

The laboratory director remains responsible for the quality of testing performed under the laboratory’s certificate, even when a POCT coordinator manages daily operations. The coordinator needs a written assignment of duties, access to the laboratory director, and clear authority to suspend a device or operator when testing is unsafe.

Stage	Required program decisions and records
Before implementation	Define clinical use, select the test system, confirm FDA categorization and intended use, establish certificate coverage, verify or establish performance, evaluate central-method comparability when applicable, and approve the procedure.
Before operator authorization	Complete training, assess competency when required, document authorization for the specific system and site, and provide access to the current procedure and manufacturer instructions.
Before patient testing	Confirm patient identity, specimen type and acceptability, reagent or cartridge lot and expiration, maintenance status, environmental limits, calibration status, and acceptable QC.
During testing and reporting	Follow the timed procedure, respond to flags and error codes, record the operator and device, transmit the result to the correct patient record, and follow the critical or unexpected-result pathway.
During continuing review	Review QC, maintenance, proficiency testing or alternative assessment, operator status, amended or suppressed results, device failures, complaints, and quality indicators across sites. Document corrective action and verify that it worked.

For the same test performed with different methods, instruments, or testing sites, CLIA requires the laboratory to evaluate and define the relationship between results at least twice each year and document the comparison.⁶ The laboratory’s procedure defines acceptance and corrective action. General method verification, statistical QC, proficiency testing, and corrective-action methods are covered in Quality Control, Method Evaluation, and Quality Management.

Training and competency

Training teaches an operator to perform the procedure. Competency assessment documents continued performance of assigned duties. CLIA applies the six-part testing-personnel competency assessment to moderate- and high-complexity testing. The assessment occurs at least semiannually during the first year in which the individual tests patient specimens in that laboratory and at least annually afterward.⁷

The six required procedures include:

direct observation of routine patient testing, including specimen handling and processing when applicable;
monitoring the recording and reporting of results;
review of worksheets, intermediate results, QC records, proficiency-testing results, and preventive-maintenance records;
direct observation of instrument maintenance, function checks, and performance;
assessment of testing with previously analyzed specimens, internal blind samples, or external proficiency-testing samples; and
assessment of problem-solving skills.

Provider-performed microscopy uses five applicable procedures and excludes direct observation of instrument maintenance and function checks for the specified manual microscopy. CLIA requires waived testing to follow the manufacturer instructions. The six-part competency assessment and federal proficiency-testing requirements apply to nonwaived testing; a state, accreditation organization, facility policy, or manufacturer may add requirements for waived testing. Proficiency-testing performance can supply one part of competency evidence, while the complete assessment documents every applicable procedure.⁷

An operator’s authorization should identify the test system and site. A new system, changed method, expired assessment, repeated QC failure, or serious testing error triggers review, retraining, reassessment, or removal of testing access according to the laboratory’s procedure.

Device labeling and result comparability

Methods that measure the same analyte can produce clinically important differences. POCT and central-laboratory systems may use different specimens, reaction principles, calibrations, measuring ranges, or interference controls. The laboratory defines the relationship before clinical use and communicates any difference that can change interpretation.

POCT application	Governance decision before use
Whole-blood glucose	Confirm that the FDA-cleared intended use covers the professional setting, specimen, and patient population. Many systems originally cleared for home use were not evaluated in critically ill patients. Define the hematocrit, perfusion, medication, environmental, and measuring-range limits that require another method.
Hemoglobin A1c	Confirm whether the device is authorized for monitoring, diagnosis, or both and whether the testing site holds the certificate required for that intended use. A rapid result can support a same-visit decision when the authorized use and clinical protocol permit it.
PT/INR	Define the device’s measuring range, specimen requirements, interferences, QC instructions, and confirmation pathway for unexpected or discordant results.
Activated clotting time or viscoelastic testing	Define the procedure, operator qualification, QC, and clinical protocol for activated clotting time during high-dose heparin use or viscoelastic testing during major bleeding. The Instrumentation module covers the detailed method principles.
Troponin	Match the assay’s intended use, decision limit, timing, and serial-testing protocol to the care pathway. Faster analytic turnaround affects care only when the surrounding response pathway uses the result promptly.
Qualitative hCG	Define the specimen types, detection limit, timing limitations, and follow-up pathway for a negative or unexpected result.
Creatinine or estimated glomerular filtration rate	Confirm that the device is authorized and locally accepted for the precontrast workflow. The local radiology and laboratory policy defines which results require another measurement.

FDA maintains separate guidance for prescription point-of-care blood-glucose systems used by health professionals. The laboratory uses a system whose labeling covers its setting and population and follows the documented limitations.⁸ For point-of-care INR meters, FDA advises routine comparison with a laboratory method and laboratory confirmation when an INR is above 4.5 because discrepancies increase at higher results. Device labeling and the laboratory’s validated procedure can add other confirmation rules.⁹

Compliance, accreditation, and quality management

Compliance is documented conformance with an applicable law, regulation, accreditation standard, manufacturer instruction, or laboratory procedure. Quality management is the continuing system that monitors processes, detects failures, investigates causes, corrects affected work, and checks the effectiveness of the correction. A successful survey documents compliance during the survey period. Continuing review determines whether the process remains controlled between surveys.

Authority or framework	Role in U.S. laboratory testing
CMS	Administers CLIA certification, surveys and enforcement; approves proficiency-testing programs and accreditation organizations; and oversees state survey agencies.
FDA	Categorizes test systems as waived, moderate, or high complexity; reviews waiver applications; and regulates in vitro diagnostic devices, blood, and biologic products through the responsible FDA centers.
CDC	Supplies technical assistance, laboratory-quality studies, educational resources, and technical support to the CLIA program.
State and local authorities	May require additional laboratory licenses, personnel licenses, reporting, or operating conditions. Washington has an HHS-approved CLIA-exempt program, and New York has a partial exemption within its authorized scope.
CMS-approved accreditation organization	Applies its standards and surveys within its approved specialties and subspecialties. Accreditation that CMS recognizes provides CLIA deemed status within that scope.
ISO 15189:2022	Provides international requirements for medical-laboratory quality and competence and states that it applies to POCT. U.S. laboratories remain subject to CLIA wherever CLIA applies.

FDA also oversees blood components, plasma derivatives, and related biologic products. Detailed requirements for registration, licensing, manufacturing, donor eligibility, deviation reporting, and recalls are covered in Blood Banking.¹⁰

The CMS list dated August 8, 2025 names seven approved CLIA accreditation organizations: AABB, the American Association for Laboratory Accreditation, Accreditation Commission for Health Care, the American Society for Histocompatibility and Immunogenetics, COLA, the College of American Pathologists, and The Joint Commission. Each organization has an approved scope, and its current standards may add requirements beyond the federal minimum.¹¹ CAP applies its laboratory and point-of-care checklists within the CAP-accredited scope; CAP released its 2025 checklist edition on December 10, 2025, and laboratories use the current applicable checklist for their inspection cycle.¹² The Joint Commission applies its laboratory and health-care accreditation requirements within the accredited program. AABB applies its accreditation requirements within approved transfusion medicine and related specialties. ISO 15189:2022 can support an international quality and competence system and expressly includes POCT.¹³

For each nonwaived specialty, subspecialty, analyte, or test covered by the required CLIA proficiency-testing list, the laboratory enrolls each certificate in an HHS-approved program. Routine personnel test the samples with the routine system and workflow. Referral for analysis to another laboratory that is certified to perform that testing is prohibited. Tests outside the required list use the applicable accuracy-verification process, including twice-yearly assessment when CLIA requires it. Waived testing follows the manufacturer instructions and any external-assessment requirement imposed by the state, accreditation organization, or laboratory policy. Detailed proficiency-testing rules are covered in Quality Control, Method Evaluation, and Quality Management.¹⁴

Certificates of Compliance and Accreditation undergo surveys or inspections on a two-year cycle. Certificate of Waiver and PPM sites can be inspected for a complaint, testing outside certificate scope, risk of harm, or program information collection. CLIA enforcement can include a directed plan of correction, state on-site monitoring, civil monetary penalties, or limitation, suspension, or revocation of a certificate, depending on the deficiency and governing process.⁴

References

Centers for Disease Control and Prevention. Test complexities. Accessed August 29, 2026.
Electronic Code of Federal Regulations. 42 CFR part 493: Laboratory Requirements. Updated through August 27, 2026. Accessed August 29, 2026.
US Food and Drug Administration. CLIA categorizations. Accessed August 29, 2026.
Centers for Medicare & Medicaid Services. CLIA Program & Medicare Laboratory Services. MLN006270. Revised March 2026.
Electronic Code of Federal Regulations. 42 CFR §493.35: Application for a certificate of waiver. Updated through August 27, 2026. Accessed August 29, 2026.
Electronic Code of Federal Regulations. 42 CFR §493.1281: Standard: Comparison of test results. Updated through August 27, 2026. Accessed August 29, 2026.
Centers for Medicare & Medicaid Services. Assessing Personnel Competency. Revised May 2025.
US Food and Drug Administration. Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use: Guidance for Industry and Food and Drug Administration Staff. Issued September 29, 2020.
US Food and Drug Administration. Information for health care providers using INR test meters in a clinical setting. Accessed August 29, 2026.
US Food and Drug Administration. Blood and blood products. Accessed August 29, 2026.
Centers for Medicare & Medicaid Services. List of approved accreditation organizations under the Clinical Laboratory Improvement Amendments. Version 8.8.2025.
College of American Pathologists. CAP puts patient safety and regulatory clarity at the forefront with new laboratory checklist. Published December 10, 2025.
International Organization for Standardization. ISO 15189:2022: Medical laboratories: Requirements for quality and competence. 4th ed. Published December 2022.
Electronic Code of Federal Regulations. 42 CFR §493.801: Condition: Enrollment and testing of samples. Updated through August 27, 2026. Accessed August 29, 2026.